Endoline
1002.392.357 · rovalta.com · 09/11/2026
Endoline
Financial year 2026 · Closed on 30/06/2026
Overview
Identity
Source · BCE/KBOEndoline is a Private limited company incorporated in 2023. Its main activity is: Specialist medical practice activities. Its registered office is in Lille.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 1002.392.357
- Incorporation
- 17/11/2023
- Legal form
- Private limited company
- Registered office
- Gagelveld 29
2275 Lille · FlandreSee on map - Contributed capital
- 3 000,00 €
- Latest accounts
- 30/06/2026
Financials
Source · NBB, 3 filingsTrend over 3 financial years
| 2026 | 2025 | 2024 | |||
|---|---|---|---|---|---|
| Income statement | |||||
| Gross margin | 187,9 k € | +83.7% | 102,3 k € | +168% | 38,1 k € |
| EBITDA | 187,1 k € | +85.8% | 100,7 k € | +172% | 37 k € |
| Operating result | 174,8 k € | +87.5% | 93,2 k € | +152% | 37 k € |
| Net result | 134,8 k € | +83.9% | 73,3 k € | +151% | 29,2 k € |
| Balance sheet | |||||
| Equity | 240,3 k € | +128% | 105,5 k € | +228% | 32,2 k € |
| Total assets | 314,3 k € | +85.6% | 169,3 k € | +296% | 42,8 k € |
| Cash | 189,8 k € | +183% | 66,9 k € | +958% | 6,3 k € |
| Debts | 74 k € | +15.9% | 63,9 k € | +503% | 10,6 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 30/06/20261 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Eveline LEFEVER | Directorsince 16/11/2023 |
Financials
Full financial information
Source · NBB| 2026 | 2025 | 2024 | |
|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model |
| Start of the financial year | 01/07/2025 | 01/07/2024 | 20/03/2023 |
| Closing of the financial year | 30/06/2026 | 30/06/2025 | 30/06/2024 |
| Length of the financial year | 12 months | 12 months | 16 months |
| Filing date | 02/11/2026 | 17/12/2025 | 15/11/2024 |
| General meeting | 02/10/2026 | 09/12/2025 | 08/11/2024 |
| Currency of the financial year | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 3 filingsValuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 30/06/20261 active
Active mandates
| Director | Mandates in this company | Period |
|---|---|---|
Eveline LEFEVER | Directorsince 16/11/2023 |
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Other21/11/2023RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsRegistered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Gagelveld 29, 2275 LilleCurrent | accounts 2024 → 2026 | Accounts 2026 · 2026-00600474 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| EndolineCurrent | accounts 2024 → 2026 | Accounts 2026 · 2026-00600474 |
Events
- 2026Annual accounts 2026134,8 k €↑
- 2025Annual accounts 202573,3 k €↑
- 2024Annual accounts 202429,2 k €
- 17/11/2023IncorporationPrivate limited company